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Rapport de synthèse 
L'étude CoLaus : Une étude populationnelle afin d'investiguer l'épidémiologie et 
les déterminants génétiques des facteurs de risque cardiovasculaire (FRCV) et le 
syndrome métabolique. 
Les maladies cardio-vasculaires constituent les causes principales causes de morbidité 
et de mortalité dans les pays industrialisés. Des études épidémiologiques ont démontré 
l'implication de facteurs de risques comme l'hypertension, l'hypercholestérolémie, 
l'obésité abdominale, le diabète et le tabagisme dans le développement des affections 
cardiovasculaires comme l'infarctus du myocarde ou l'accident vasculaire cérébral. De 
larges études génétiques cas-contrôle ont contribué modestement à l'identification de 
gènes de susceptibilité au développement de ces FRCV. Une étude populationnelle 
offre par contre l'avantage d'effectuer des études associatives pour des traits 
phénotypiques continus correctement mesurés et aussi pour des traits de catégories 
utilisant des protocoles d'étude cas-contrôle très discordants. Elle permet 
l'exploration des déterminants génétiques comme par exemple le syndrome 
métabolique. Cette approche permet également de procéder à des analyses de 
séquençage sur l' ADN des participants chez qui un trait phénotypique spécifique est 
étudié mais distribué de manière opposée. A titre d'exemple, le séquençage de l'ADN 
de participants à taux très élevé d'HDL-cholestérol versus très bas de ce marqueur 
lipidique permet d'identifier des variants génétiques rares localisés sur les parties 
codantes de gènes spécifiques associés aux dyslipidémies. 
Pour ce faire, nous avons recruté 6'188 personnes âgées de 35 à 75 ans, d'origine 
caucasienne et résidant en ville de Lausanne (3251femmes et 2937 hommes). 
L'obtention d'un tel collectif a nécessité l'échantillonnage aléatoire de quelque 19'830 
personnes de cette tranche d'âge. Les participants ont fait l'objet d'une anamnèse 
approfondie et d'un examen clinique. Le bilan était complété par une prise de sang 
pour le dosage de paramètres biologiques ainsi qu'une analyse génétique. Cette 
dernière a été effectuée après extraction d' ADN au moyen d'une puce Affimetrix qui 
évalue la présence de quelques 500'000 SNPs. 
Les données récoltées lors de cette étude dévoilent que l'obésité (index de masse 
corporelle 2': 30 kg/m2), le tabagisme, l'hypertension (pression artérielle 2': 140/90 
mmHg et/ou hypertension traitée), une dyslipidémie (LDL cholestérol élevé et/ou 
HDL cholestérol bas et/ou triglycéride élevé) et le diabète (glucose à jeun 2': 7 mmol/l 
et/ou traitement) affectent respectivement 947 (15,7%), 1673 (27%), 2268 (36,7%), 
2113 (34,2%) et 407 (6,6%) participants. La prévalence de ces FRCV est plus marquée 
chez les hommes que chez les femmes. Dans les deux genres les prévalences de 
l'obésité, de l'hypertension et du diabète augmentent drastiquement avec l'âge. 
En conclusion la prévalence des FRCV est élevée au sein d'une population 
représentative de Lausanne âgée de 35 à 75 ans. A l'avenir, l'étude CoLaus constituera 
par la richesse de ses données phénotypiques et génétiques, une source unique pour 
investiguer l'épidémiologie et l'identification de gènes associés à ces FRCV. 
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Abstract 
Background: Cardiovascular diseases and their associated risk factors remain the main cause of mortality in western societies. 
ln order to assess the prevalence of cardiovascular risk factors (CVRFs) in the Caucasian population of Lausanne, Switzerland, 
we conducted a population-based study (Colaus Study). A secondary aim of the CoLaus study will be to determine new genetic 
determinants associated with CVRFs. 
Methods: Single-center, cross-sectional study including a random sample of 6, 188 extensively phenotyped Caucasian subjects 
(3,251 women and 2,937 men) aged 35 to 75 years living in Lausanne, and genotyped using the 500 K Affymetrix chip technology. 
Results: Obesity (body mass index::': 30 kg/m2), smoking, hypertension (blood pressure ::': 140/90 mmHg and/or treatment), 
dyslipidemia (high LDL-cholesterol and/or low HDL-cholesterol and/or high triglyceride levels) and diabetes (fasting plasma 
glucose::': 7 mmol/I and/or treatment) were present in 947 ( 15.7%), 1673 (27.0%), 2268 (36.7%), 2113 (34.2%) and 407 (6.6%) 
of the participants, respectively, and the prevalence was higher in men than in women. ln both genders, the prevalence of obesity, 
hypertension and diabetes increased with age. 
Conclusion: The prevalence of major CVRFs is high in the Lausanne population in particular in men. We anticipate that given 
its size, the depth of the phenotypic analysis and the availability of dense genome-wide genetic data, the CoLaus Study will be a 
unique resource to investigate not only the epidemiology of isolated, or aggregated CVRFs like the metabolic syndrome, but can 
also serve as a discovery set, as well as replication set, to identify nove! genes associated with these conditions. 
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Background 
Cardiovascular diseases (CVD) are the major cause of 
early mortality and morbidity in industrialized countries 
[ 1]. The prevalence of classical cardiovascular (CV) risk 
factors (CVRFs) such as hypertension, dyslipidemia, obes-
ity and diabetes varies widely between different countries, 
and shows some important secular trends 
Hypertension, obesity, dyslipidemia and diabetes melli-
tus have an important genetic component [2,3]. These 
conditions, however, are genetically complex, and only a 
small fraction of these diseases are accounted for by Men-
delian forms. The availability of large case-contrai 
genome-wide association studies has led to the identifica-
tion of susceptibility genes for common conditions, with 
even modest effects. Population-based studies have addi-
tional advantages; they make it possible to perform asso-
ciation studies for any continuous phenotypic trait which 
has been properly monitored, as well as for categorical 
traits using extreme discordant case-contrai designs, as 
long as these conditions are sufficiently prevalent. In addi-
tion, they offer the opportunity to explore the genetic 
determinants of aggregated phenotypes such as the meta-
bolic syndrome. Finally, this type of studies provide the 
opportunity to perform re-sequencing analysis on 
extremes of the distribution, and to identify rare genetic 
variants with a strong phenotypic effect [ 4]. The success of 
such studies relies on a large collection, detailed and 
standardized phenotypes, strong analytical capabilities, 
replication sets and extensive genotyping [5]. To hamess 
the power of these technologies, we designed the Co Laus 
study. The major goals of the CoLaus Core study were to 
get a snap picture of the prevalence and severity of CVRFs 
in a particular population and to elucidate the molecular 
architecture of isolated CVRFs, as well as clusters of CVRFs 
like the metabolic syndrome. In this article, we present the 
protocol of the study as well as results for the prevalence 
of multiple cardiovascular risk factors the Lausanne pop-
ulation. 
Methods 
Recruitment process and somple size 
The Study was approved by the Institutional Ethic's Com-
mittee of the University of Lausanne and recruitment took 
place in the city of Lausanne in Switzerland, a town of 
117,161 inhabitants, of which 79,420 are of a Swiss 
nationality[ 6]. 
The complete list of the Lausanne inhabitants aged 35-75 
years (n = 56,694 in 2003) was provided by the popula-
tion register of the city and served to sample the partici-
pants to the study. Ali subjects living in the city of 
Lausanne in 2003 for more than 90 days have their name 
included in this register. The register had information on 
age and gender but no information regarding ethnicity or 
country of origin. 
http://www.biomedcentral.com/1471-2261/8/6 
Given the allele frequency of most SNPs on the Affymetrix 
chip and the genetic effect sizes expected for complex dis-
eases (i.e. OR 1.3 and above), we chose to include ru6000 
individuals, so as to have enough power ( ru80%) ta detect 
genetic associations for diseases with a prevalence of 
rul5%. 
A simple, non-stratified random selection of 19,830 sub-
jects, corresponding to 35% of the source population, was 
drawn using STATA v9.1 software (Stata Corp, College 
Station, USA), and a letter inviting the addressee to partic-
ipate in the study was sent to these individuals. 
Subjects who volunteered to participate were contacted by 
phone within 14 days by one of the staff members to set 
up an appointment. Subjects who didn't answer were sent 
a second invitation letter. If no answer was obtained, they 
were contacted by phone. Subjects were considered as 
non-participants if they refused to participate and as non-
responders if contact couldn't be made after two succes-
sive letters and three successive phone calls. Individuals 
who didn't live in Lausanne any longer, who were dead or 
who didn't meet the age criteria were considered as non-
eligible. Recruitment began in June 2003 and ended in 
May 2006. 
The sampling procedure is summarized in Figure 1. Of the 
initial 19,830 subjects sampled, 54 subjects were consid-
ered as non-eligible before contact and 15, 109 (76%) 
responses were obtained. A total of 4667 subjects who did 
not respond were considered as non-responders. Among 
responders, 6, 189 ( 41 % ) subjects refused to participate in 
the study and 799 (5%) were considered as non-eligible. 
Among the latter, 53% moved to a different city, 32% 
were out of the age range and 11 % were reported to be 
deceased. The sample of 8, 121 subjects who agreed to par-
ticipate represented 41 % of the initially sampled popula-
tion, 54% of ail responders and 57% of ail eligible 
responders. 
Inclusion criterio 
The following inclusion criteria were applied: a) written 
informed consent; b) age 35-75 years and c) Caucasian 
origin. Caucasian origin was defined as having both par-
ents and grandparents bom in a restricted list of countries 
(available from the authors). No other exclusion criteria 
were applied. Since ethnicity could only be established 
during the clinic visit, some participants were assessed but 
were not included in the CoLaus study. Their data will be 
described elsewhere. 
Assessment process 
Participants were asked to attend the outpatient clinic at 
the Centre Hospitalier Universitaire Vaudois (CHUV) in 
the moming after an ovemight fast. They had to take their 
medication as usual. Data were collected by trained field 
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Lausanne population aged 35-75 years 
n,,,56,694 
Initial random sample 
n=19,830 (35.0%) 
Conlacted 
n=19,776 (99.7%) 
Responders 
n=15,109 (76.4%) 
Eligible for interview 
n=B,121 (41.0%) 
54 ineligible 
799 ineligible 
r--------- 1 ,383 not included 
Completed interview 
n=6,738 (83.0%) 
Non Caucasian Cohort 
r----------< n=:549 (8, 1°/6) 
Figure 1 
Colaus Study çohort 
n=6,188 (91.9%) 
Flow chart of the Colaus Study. 
1 w~hdrawal 
interviewers in a single visit lasting about 60 minutes. 
Informed consent was obtained from participants upon 
their arrivai at the study clinic. The first questionnaire 
mailed with the appointment's letter and completed by 
the participant prior to the morning visit was then quickly 
reviewed and a second questionnaire was applied by 
interview prior to clinical measurements and blood col-
lection. 
Questionnaire data 
The first set of questionnaires recorded information on 
demographic data, socio-economic and marital status, 
and several lifestyle factors, namely tobacco, alcohol and 
caffeine consumption, physical activity and mood. Data 
on smoking included the previous and current smoking 
status as well as the amount of tobacco smoked ( number 
of cigarettes, cigarillos, cigars or pipes), age of beginning 
and end (for former smokers). Similarly, data on alcohol 
http://www.biomedcentral.com/1471-2261 /8/6 
consumption included the past and current drinking sta-
tus as well as the number of alcoholic beverage units 
(wine, beer and spirits) consumed over the week preced-
ing the interview. Caffeine consumption was assessed by 
the number of caffeine-containing beverages consumed 
per day. Personal history of overweight and/or obesity 
and birth weight were also collected. Finally, the 12-item 
General Health Questionnaire (GHQ12) [7] was applied 
in order to screen for the presence of non-psychotic psy-
chiatrie disorders. 
The second questionnaire, administered during a face-to-
face meeting with the recruiter, focused on persona! and 
family history of disease and CV risk factors. Subjects were 
asked which disease( s) they or their family had presented. 
When a positive answer was given, further information 
regarding age of occurrence and number of family mem-
bers affected was collected. When appropriate, death of 
parents was recorded with age and cause of death. Regard-
ing blood pressure (BP) status, subjects indicated if they 
had been diagnosed with hypertension and subsequently 
if they had been, or were being treated currently for this 
condition. BP levels before the beginning of treatment 
were sought for and the names of the anti-hypertensive 
drugs that had been prescribed were collected. In case the 
anti-hypertensive regimen had been modified, the dura-
tion and the reason for changing were also recorded. Per-
sona! medicines, including prescription and self-
prescribed drugs, vitamin and minerai supplements, 
homeopathy or natural remedies were collected, together 
with their main indications. In women, further data 
regarding reproductive and obstetrical history, oral con-
traception and hormonal replacement therapy was col-
lected. Finally, an additional frailty questionnaire (for 
subjects aged over 50 years) and the Mini-Mental State 
Evaluation (MMSE - for subjects aged over 65 years) were 
further administered [ 8]. 
C/inical data 
Body weight and height were measured with participants 
standing without shoes in light indoor clothes. Body 
weight was measured in kilograms to the nearest 0.1 kg 
using a Seca" scale (Hamburg, Germany), which was cali-
brated regularly. Height was measured to the nearest 5 
mm using a Seca" height gauge (Hamburg, Germany). 
Body mass index (BMI) was defined as weight/height2. 
Obesity was defined as BMI;:: 30 kg/m2 and overweight as 
BMI;:: 25 kg/m2 and< 30 kg/m2. 
BP and heart rate were measured thrice on the left arm, 
with an appropriately sized cuff, after at least 10 minute 
rest in the seated position using an Omron® HEM-907 
automated oscillometric sphygmomanometer (Matsu-
saka, J a pan) [ 9]. The average of the last two measurements 
was used for analyses. Hypertension was defined as a 
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systolic BP (SEP) 2 140 mm Hg and/or a diastolic BP 
(DEP) 2 90 mm Hg during the visit and/or presence of 
anti-hypertensive drug treatment and was considered as 
known if the subject was aware of this condition. 
In addition, waist and hip circumferences were measured 
as recommended [10] and fat and fat-free mass were 
assessed by electrical bioimpedance [11] using the Bodys-
tat® 1500 analyzer (Isle of Man, British Isles). Finally, 
baldness and its age of onset were assessed in men using 
the Hamilton scale [12]. 
Sub-studies 
In addition, sub-studies designed to assess the psychiatrie 
characteristics of this population as well as functional CV 
measurements, were nested onto this study, and will be 
described separately. 
Biologica/ data 
Venous blood samples (50 ml) were drawn after an over-
night fast, and most clinical chemistry assays were per-
formed by the CHUV Clinical Laboratory on fresh blood 
samples whereas Pathway Diagnostics (Los Angeles, CA) 
measured adiponectin, leptin and insulin [See additional 
file 1]. Additional aliquots were stored at -80 ° C. 
LDL-cholesterol was calculated with the Friedewald for-
mula only if triglycerides <4.6 mmol/l. Low HDL choles-
terol level was defined as <1.0 mmol/L; high HDL 
cholesterol as 2 1.6 mmol/L; high LDL cholesterol was 
defined as 2 4.1 mmol/L and high triglyceride level was 
defined as 2 2.2 mmol/L [13]. In our analysis, dyslipi-
demia was defined as low HDL cholesterol and/or high 
triglyceride and/or LDL cholesterol 2 4.1 mmol/L or 2 2.6 
mmol/L in presence of self-reported history of myocardial 
infarction, stroke, coronary artery disease or diabetes. 
Diabetes was defined as fasting plasma glucose 2 7.0 
mmol/L and/ or presence of oral hypoglycaemic or insulin 
treatment. Type 2 diabetes mellitus (T2DM) was defined 
in case of diabetes without self-reported Type 1 DM. Dia-
betes was considered as known if the subject was aware of 
this condition. Impaired fasting glucose (IFG) was 
defined as fasting plasma glucose between 6.1 and 6.9 
mmol/L without anti-diabetic treatment [14]. 
A urine sample was collected for the assessment of creati-
nine and albumin and the albumin-to-creatinine ratio 
was calculated. Microalbuminuria was defined as a value 
of albumin-to-creatinine ratio above 30 mg/g. 
Genotyping 
Nuclear DNA was extracted from whole blood for whole 
genome scan analysis and genotyping was performed 
using the Affimetrix 500 K SNP chip, as recommended by 
http://www. biomedcentral .com/14 71-2261 /8/6 
the manufacturer. Subjects consented for the genetic data 
to be used for the study of cardiovascular risk factors, and 
associated diseases including mood disorders. 
Data management, security and quality contrai 
Data were entered into a secured, internet-based database. 
The database was designed to confirm the validity of the 
identification codes, establish the completeness of the 
information keyed in and to perform basic data checks. 
All discrepancies were recorded in the case report form 
kept in a locked room. Each modification of the data was 
automatically recorded, including the identity of the 
investigator who made the modification, the date, the old 
and the new value. 
Staff members were trained and certified before being 
involved actively in the study. Certification included abil-
ity to conduct interviews, to perform phlebotomy and to 
process blood samples, to accurately measure anthropo-
metric and BP levels and to enter data into electronic data-
bases. The accurateness of the data was checked by an 
external quality control organization (PRN, North Hamp-
shire, United Kingdom). 
Finally, the 'Laboratoire Central du CHUV' is ISO 9001 
certified and is regularly checked by the "Centre Suisse de 
Contrôle de Qualité" (CSCQ - Swiss Centre for Quality 
Control). 
Power estimates and type I error rate 
Power calculations were done using the program Quanta 
vl.1 (James Gauderman, University of Southern Califor-
nia, USA) [15]. Power for unmatched case-control studies 
was estimated using an arbitrary allelic frequency ranging 
from 0.1 to 0.5, an additive model, a disease prevalence of 
50% and a type 1 error rate of 10-7, which was used as a 
correction for multiple testing taking into account 
500'000 genetics markers. Curves were drawn for esti-
mated genetic effect sizes ( odds ratios) of 1.2 to 1.8. To 
estimate power in a continuous trait analysis, SEP was 
used as a continuous outcome for independent subjects, 
with an additive model and a type 1 error rate of 10-7 . 
Curves were drawn for various minor allele frequencies 
(0.1 to 0.5). To minimize false positive results, the most 
significant genetic markers will be replicated in independ-
ent samples. 
Statistical analysis 
Statistical analyses were performed using Stata 9 .1 ( Stata 
Corp, College Station, USA). Results were expressed as 
mean ±standard deviation (SD) or as number of subjects 
and (percentage). Data for age group 35-75 years and for 
the canton de Vaud were extracted from the MONICA 
population surveys and used to assess trends [16]. Age at 
sampling was used for comparisons between the initial 
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population, the random sample and the CoLaus study 
population, whereas age at examination was used to 
describe the CoLaus Study group characteristics. Compar-
isons were performed using Student's t-test or chi-square 
test for quantitative and categorical variables, respectively. 
Statistical significance was assessed for p < 0.05. 
Sponsoring 
The Study was sponsored in part by GlaxoSmithKline and 
ail participants were duly informed about this sponsor-
ship and consented for the use of biological samples and 
data by GlaxoSmithKline and its subsidiaries. 
Results 
Recruitment 
A total of 8121 individuals volunteered to participate in 
the study. Among these subjects, the first 6, 738 were 
invited to attend the clinic and completed the examina-
tion. 549 participants ( 8.1 % ) were not of Caucasian eth-
nicity and were excluded from the CoLaus study and 
6, 189 participants met the inclusion criteria (including 
ethnicity) and were included in the CoLaus study. As the 
number of subjects who agreed to participate ( 8, 121) was 
higher than the number of subjects initially planned for 
the CoLaus study (6,000), 1,383 could not be included 
into the study although they were willing to participate. 
One subject withdrew after consent due to persona! rea-
sons. Overall, the final CoLaus sample (n = 6,188) repre-
sents 43% of the eligible responders, 41 % of all the 
responders and 31 % of the initially sampled population. 
The gender and age characteristics of the source popula-
tion, the initial random sample and the final CoLaus sam-
ple are summarized in Table 1. Overall, both the sampled 
population and the CoLaus study participants were on 
average one year younger than the base population, due to 
an under-representation of subjects aged over 65 years 
while no differences were found for gender distribution. 
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Further, after excluding non-eligible subjects, no differ-
ences were found regarding mean age and gender distribu-
tion between the subjects included and the random 
sample (not shown). The CoLaus Study participants were 
significantly older (51.1 ± 0.1 vs. 50.8 ± 0.1 years, p < 
0.005) than the random sample, while no differences 
were found for gender distribution (not shown). Age at 
examination of the participants was on average 2 years 
higher than age at sampling because of the time elapsed 
between the two procedures. Distribution of the zip codes 
within the city was comparable between the base popula-
tion, the random sample and the CoLaus study partici-
pants (not shown). 
Socio-economic characteristics of the CoLaus study 
participants 
The CoLaus Study participants' main characteristics are 
summarized in Table 2. No gender differences were found 
regarding the percentage of foreigners. Overall, women 
were more frequently divorced, widowed or single than 
men and thus were living more often alone or as a mon-
oparental family (41.7% vs. 23.6%, p < 0.01). Women 
were also Jess frequently on a full-time job, more prone to 
receive social help (26.2% vs. 22.2%, p < 0.001) and had 
a lower educational level. Among subjects aged Jess than 
40 years old, 48.4% ofwomen had a high school/college/ 
university degree versus 47.4% of men (p < 0.01). 
Clinical characteristics of the CoLaus Study participants 
Men had a higher BMI, waist/hip ratio, systolic and DEP 
levels, but lower body fat percentage, than women. [Table 
3]. Men had higher total cholesterol and triglyceride lev-
els, but lower HDL cholesterol, than women. Fasting 
blood glucose levels, homocystein, apolipoprotein B, 
insulin, NT-proBNP and uric acid were higher in men 
than in women [Tables 3 and 4]. Conversely, women pre-
sented higher LDL cholesterol particle size, adiponectin, 
leptin and hsCRP than men. 
Table 1: Distribution of participants by age and sex in the source population, the initial random sample and the Colaus Study 
participants. 
Source population (n = 56,694) Random sample (n = 19,830) Colaus Study (n = 6, 188) 
Women (%) 30, 141 (53.4) 10,601 (53.5) 3,251 (52.5) 
P value 0.79 0.08 
Age (years) 52.0 ± 11.6 50.8 ± 11.5 51.I ± 10.9 
P value <0.001 <0.001 
Age group 
35-44 18.877 (33.4) 7,265 (36.6) 2,05 1 (33.1) 
45-54 14,614 (25.9) 5,202 (26.2) 1,682 (27.2) 
55-64 12.484 (22.1) 4,417 (22.3) 1,65 7 (26.8) 
65-75 10,524 ( 18.6) 2,946 (14.9) 798 (12.9) 
P value <0.001 <0.001 
Results are expressed as number of subjects and (percentage) or as mean ± SD. Statistical analysis by Student's t-test or chi-square test compared 
ta the source population 
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Table 2: Socio-economic characteristics of the participants in the Colaus Study. 
Overall (n = 6, 188) Women (n = 3,251) Men (n = 2,937) P value 
Born in Switzerland (%) 3,997 (64.6) 2, 129 (65.5) 1,868 (63.6) 0.12 
Marital status (%) 
Single 1,022 ( 16.5) 569 (17.5) 453 ( 15.4) 
Married 3,635 (58.8) 1,673 (51.5) 1,962 (66.9) <0.001 
Divorced 1,242 (20.1) 761 (23.4) 481 (16.4) 
Widowed 287 (4.6) 248 (7.6) 39 (1.3) 
Education (%) 
Basic 1,287 (20.8) 777 (23.9) 510 (17.4) 
Apprenticeship 2,286 (3 7.0) I, 170 (36.0) 1, 1 16 (38.0) <0.001 
High school/college 1,470 (23.9) 804 (24.8) 666 (22.7) 
University 1, 140 ( 18.4) 497 (15.3) 643 (21.9) 
Work status (%) 
Full time 3,790 (61.2) 1,694 (52.1) 2,096 (71.4) <0.001 
Other 2,398 (38.8) 1,557 (47.9) 841 (28.6) 
Results are expressed as number of subjects and (percentage). Comparison between gender was performed using chi-square test. 
Table 3: Clinical characteristics of the participants in the Colaus study, by gender. 
Overall (n = 6, 188) Women (n = 3,251) Men (n = 2,937) P value 
Age (years) 53.1±10.8 53.5 ± 10.7 52.6 ± 10.8 <0.001 
Waist/hip ratio 0.88 ± 0.08 0.83 ± 0.07 0.93 ± 0.06 <0.001 
BMI (kg/m2) 25.8 ± 4.6 25.I ± 4.9 26.6 ± 4.0 <0.001 
Body fat(%) 29.3 ± 9.0 34.4 ± 8.2 23.8 ± 6.1 <0.001 
Systolic BP (mm Hg) 128 ± 18 125 ± 18 132 ± 17 <0.001 
Diastolic BP (mm Hg) 79 ± 11 78 ± 11 81 ± 11 <0.001 
Total cholesterol (mmol/L) 5.59 ± 1.04 5.61 ± 1.03 5.56 ± 1.04 <0.05 
HDL cholesterol (mmol/L) 1.63 ± 0.44 1.81±0.43 1.44 ± 0.36 <0.001 
Triglycerides (mmol/L) 1.40 ± 1.18 1.16 ± 0.66 1.66 ± 1.52 <0.001 
LDL cholesterol particle size (nm) 272 ± 4 273 ± 4 271 ± 5 <0.001 
Apolipoprotein B (mg/dl) 1.74 ± 1.34 1.69 ± 1.29 1.80 ± 1.38 <0.005 
Glucose (mmol/L) 5.55 ± 1.15 5.34 ± 1.02 5.78 ± 1.23 <0.001 
lnsulin (~1U/ml) 8.44 ± 6.3 7.97 ± 5.47 9.62 ± 6.78 <0.001 
Adiponectin (µg/ml) 9.94±8.12 12.32 ± 9.33 7.32 ± 5.43 <0.001 
Leptin (ng/ml) 13.1 ± 10.7 16.9 ± 11.7 8.65 ± 7.3 <0.001 
Homocystein (µmol/L) 10.4 ± 4.4 9.4 ± 3.2 11.4 ± 5.2 <0.001 
hsCRP (mg/L) 2.49 ± 3.48 2.65 ± 3.71 2.30 ± 3.21 <0.001 
Pro-BNP (ng/L) 682 ± 531 679±519 686 ± 545 0.60 
Results are expressed as mean ± SD. BMI: body mass index; HDL: high density lipoprotein, hsCRP: high sensitivity C-reactive protein, BNP: brain 
natriuretic peptide. Statistical analysis between gender by Student's t-test or chi-square test. 
CVRFs within the CoLaus study 
More than one third of the overall sample was overweight, 
and slightly less than one-sixth was obese; overweight and 
obesity were also more prevalent in men [Table 5] and 
increased with age. In men aged 35-44 years, the preva-
lence of overweight and obesity were 40. 7% and 11.4%, 
respectively, whereas in men aged 65-75 the correspond-
ing figures were 50.8% and 22.7% (p < 0.001). The corre-
sponding figures for women were 21.9% and 9.6%, and 
35.8% and 17.5% (p < 0.001), respectively. 
Smoking was reporter by 27% of the participants; the 
prevalence of current smoking was higher in men and 
tended to decrease with age, from 35.3% among 35-44 
year olds to 20.7% among 65-75 year olds in men (p < 
0.001), the corresponding figures being 28.1%and14.7% 
in women (p < 0.001). Interestingly, in the 45-54 age 
class, prevalence of smoking was higher in women than in 
men (30.7% vs. 28.8% (p < 0.001)). 
The prevalence of hypertension was 36.7% overall, was 
higher in men and increased with age: 18.3% and 75.1 % 
in men aged 35-44 and 65-75, respectively (p < 0.001); 
the corresponding numbers in women were 9.9% and 
59.1% (p < 0.001). Among hypertensive subjects, 50.1% 
were currently taking anti-hypertensive medication. Treat-
Page 6of11 
(page number not for citation purposes) 
BMC Cardiovascu/ar Disorders 2008, 8:6 http://www.biomedcentral.com/14 71-2261 /8/6 
Table 4: Clinical characteristics of the participants of the CoLaus study, by gender. 
Overall (n = 6, 188) Women (n = 3,251) Men (n = 2,937) P value 
ASAT (U/L) 29.96 ± 14.04 26.22 ± 9.88 34.10 ± 16.57 <0.001 
ALAT (U/L) 27.84 ± 19.50 21.98 ± 14.47 34.32 ± 22.13 <0.001 
Alkaline phosphatase (U/L) 63.47 ± 20.72 62.66 ± 20.99 64.38 ± 20.38 <0.001 
Gamma-GT (U/L) 33.20 ± 59.04 22.95 ± 25.78 44.57 ± 79.80 <0.001 
Calcium (mmol/L) 2.29 ± 0.09 2.28 ± 0.10 2.29 ± 0.09 <0.001 
Albumin (g/L) 44.20 ± 2.53 43.73 ± 2.48 44.71 ± 2.48 <0.001 
Total protein (g/L) 74.41 ± 4.39 73.93 ± 4.42 74.95 ± 4.30 <0.001 
Urie acid (µmol/L) 313.49 ± 84.47 270.56 ± 67.23 361.08 ± 75.69 <0.001 
CDT (% of total transferrin) 0.95 ± 0.81 0.80 ± 0.48 1.12 ± 1.02 <0.001 
Results are expressed as mean ± SD. ASAT: Aspartate amino-transferase. ALAT: Alanine amino-transferase. Gamma-GT: Gamma-glutaryl-
transferase. CDT: Carbohydrate deficient transferrin. Statistical analysis between genders by Student's t-test or chi-square test. 
Table 5: Prevalence of selected cardiovascular risk factors in the participants of the CoLaus study. 
Overall (n = 6, 188) 
BMI status (%) 
Overweight 2265 (36.6) 
Obesity 974 (15.7) 
Smoking status (%) 
Current 1673 (27.0) 
Former 2034 (32.9) 
Never 2479 (40.1) 
Blood pressure status (%) 
Hypertension 2268 (36.7) 
T reated hypertension 1131 (50.1) 
T reated to goal 542 (48.0) 
Lipid status (%) 
High LDL cholesterol 1263 (20.8) 
High triglycerides 773 (12.5) 
Low HDL cholesterol 170 (2.8) 
High HDL cholesterol 3296 (53.4) 
Dyslipidemia 2113 (34.2) 
Treated dyslipidemia 286 (13.5) 
Glycaemic status (%) 
Diabetes 407 (6.6) 
Known Diabetes 270 (66.3) 
T reated Diabetes 260 (96.3) 
Microalbuminuria (%) 380 (6.3) 
Women (n = 3,251) 
922 (28.4) 
472(14.5) 
813 (25.0) 
904 (27.8) 
1534 (47.2) 
1004 (30.9) 
537 (53.8) 
271 (50.6) 
631(19.5) 
216 (6.7) 
35 (1.1) 
2324 (71.6) 
862 (26.6) 
95 (11.0) 
130 (4.0) 
89 (68.5) 
85 (95.5) 
173 (5.4) 
Men (n = 2,937) 
1343 (45.7) 
502 (17.1) 
860 (29.3) 
1130 (38.5) 
945 (32.2) 
1264 (43.0) 
594(47.1) 
271 (45.6) 
632 (22.2) 
557 (19.0) 
135 (4.6) 
972 (33.2) 
1251 (42.7) 
191 ( 15.3) 
277 (9.5) 
181 (65.3) 
175 (96.7) 
207 (7.3) 
P value 
<0.001 
<0.001 
<0.001 
<0.005 
NS 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.005 
<0.01 
Overweight: BMI ;::: 25 kg/m2. Obesity: BMI ;::: 30 kg/m2. Hypertension: Blood pressure;::: 140/90 mmHg and/or presence of anti-hypertensive 
drug treatment. Low HDL cholesterol: < 1 mmol/L; high HDL cholesterol:;::: 1.6 mmol/L; high LOL cholesterol:;::: 4.1 mmol/L and high 
triglyceride:;::: 2.2 mmol/L. Dyslipidemia: low HDL cholesterol and/or high triglyceride and/or LDL cholesterol;::: 4.1 mmol/L or;::: 2.6 mmol/L in 
presence of self-reported myocardial infarction, stroke, coronary artery disease or diabetes. Diabetes: fasting plasma glucose;::: 7 mmol/L and/or 
presence of oral hypoglycaemic or insulin treatment. Microalbuminuria :albumin-to-creatinine ratio > 30 mg/g 
ment for hypertension was more frequent in female sub-
j ects and increased with age (from 32.2% to 59.4%). Of 
the treated hypertensive subjects more than half (52.0%) 
had BP levels 2 140/90 mmHg. 
High LDL cholesterol, high triglyceride and low HDL cho-
lesterol levels were seen in 20.8%, 12.5% and 2.8% of the 
subjects, respectively and these conditions were also more 
prevalent in men. The prevalence ofhigh HDL cholesterol 
was 53.4% and higher in women than men (71.6% vs. 
33.2%). Overall, one third of the sample had dyslipi-
demia, the prevalence of which was higher in men 
(42.7%) than in women (26.6%). 
Use of statin therapy in subjects with high LDL cholesterol 
was 5.6%. Prevalence of statin therapy was 69% in sub-
jects after myocardial infarction, 33% in subjects after 
stroke and 70% in subjects after coronary artery bypass 
graft. Target level of LDL-cholesterol for secondary pre-
vention, as recommended ( < 2.6 mmol/l), was achieved 
in 28%, 38%, 28% and 33% of the subjects with diabetes, 
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myocardial infarction, stroke and coronary artery bypass 
graft, respectively. 
The overall prevalence of diabetes was 6.6%, and was 
higher in men. Nine subjects (2.2%) reported to have 
TlDM. The prevalence of diabetes increased with age, 
from 2.5% to 17.2% in men aged 35-44 and 65-75, 
respectively; the corresponding numbers were 1.2% and 
9.0% in women with a peak prevalence of 17.2% in men 
aged > 65. Roughly a third were newly diagnosed diabetics 
(31.5% forwomen and 34.7% for men, respectively). The 
prevalence ofIFG in the CoLaus population was 9.8% and 
was higher in men than in women (14.3% vs. 5.6%). 
Treatment for diabetes was present in 73.9% of diabetic 
subjects but nearly all known diabetics were treated 
(96.3% ). Of the treated diabetic subjects 63.9% had a fast-
ing blood glucose ;::: 7 mmol/L, at the time of their visit. 
Finally, 0.7% ofwomen and 2.6% of men reported a per-
sona! history of myocardial infarction (p < 0.001); con-
versely, no gender differences were found regarding 
personal history of stroke: 1.0% of women vs. 1.3% of 
men, p = 0.16. 
Power estimates 
The power of the CoLaus study for an unmatched case-
control design to study genotype/phenotype associations 
depends on the number of cases/contrais and estimated 
effect size [Figure 2]. For hypertension with 2268 cases, 
the estimated power is 0.9 for a 1.4 effect size and 0.5 for 
a 1.3 effect size. Cases for main CVRFs in the CoLaus study 
are: dyslipidemia: 2021, obesity: 974, smoking(> 25 cig-
arettes/day): 746, Type 2 diabetes: 398, coronary heart 
disease: 262, low HDL: 170. For continuous trait analysis, 
the example of SEP was taken [Figure 3]. For allelic fre-
quencies of 0.2 to 0.4, the study has an estimated power 
of >0.8 to detect BP variations of 2.0 - 2.3 mm Hg. 
Discussion 
Described in this report are the rationale, objectives, 
methods and first results from the CoLaus study, a single-
center population-based sample including 6188 exten-
sively phenotyped Caucasian subjects aged 35-75. Our 
results indicate that the prevalence of major CVRFs is 
high, in particular in men. In addition, this collection rep-
resents a powerful tool to identify new molecular determi-
nants of CVRFs and associated diseases [ 17]. 
The participation rate of 41 % in the Co Laus study is com-
parable to the MONICA surveys conducted in Switzerland 
and in France [ 18]. The lower response rate among elderly 
subjects is in agreement with previous data [19] and 
might be related to a lower interest for the study. How-
ever, the distribution of age groups 35-54 and 55-75 in 
http://www.biomedcentral.com/1471-2261 /8/6 
the CoLaus study was comparable to the source popula-
tion [Table l]. Also, there was no gender or zip code dis-
tribution difference between the source population, the 
random sample and the CoLaus participants. Although 
the optimal sampling frame would have consisted of a list 
of all Caucasians living in the city, information on ethnic-
ity was not available to the investigators before examina-
tion and it is not possible to assess whether ethnicity had 
an effect on the participation rate. 
The prevalence of main CVRFs was high in the CoLaus 
participants. Roughly over half of the participants pre-
sented with overweight and obesity, over a third had high 
BP or dyslipidemia white one in 15 participants had dia-
betes. 
In agreement with the literature [20], men had a higher 
prevalence of obesity and overweight than women. Fur-
ther, comparison with data from the MONICA study sug-
gests that the prevalence of obesity is increasing, which 
confirms what has been found in the nearby city of 
Geneva [21]. Compared to data from the National Health 
Examination Survey (NHANES) in the United States 
(1999-2004), the prevalence of obesity remains lower in 
Lausanne(22]. The higher prevalence of overweight in 
men might also account for their higher prevalence of dia-
betes and hypertension. In clinicat practice, the diagnosis 
of hypertension relies on several consecutive BP measure-
ments but as in most epidemiological studies, BP meas-
urements were conducted during a single visit [23]. 
Terminal digit preference in BP readings may induce a 
bias, a consistency check was conducted showing no sig-
nificant deviation of terminal digit frequency from the 
10% value for all BP measurements (not shown). The 
prevalence of hypertension was higher in men than in 
women and increased with age. Interestingly, the gender-
specific prevalence rates found in the CoLaus study were 
similar to those previously reported for the same age 
group in Italy [24] and in nearby Geneva [21]. We also 
observed that over half of the treated hypertensive sub-
jects had a BP;::: 140/90 mmHg at the time oftheir exam-
ination, indicating the continuous need to improve 
treatment compliance. The prevalence of diabetes was 
6.6% and was significantly higher in men and in particu-
lar after the age of 55 years. These numbers are similar to 
other Swiss estimates [25] and to the KORA Augsburg 
study in the southern part of Germany [26]. About a quar-
ter of the Co Laus participants were smokers, a figure quite 
similar to the data reported for the Geneva population in 
2003 [21] and somewhat lower than those observed in 
the USA[27]. The prevalence of smoking was higher in 
men than in women, although this difference tended to 
decrease among younger age groups, as previously 
reported [28]. Indeed, in the age group 45-54, the preva-
lence of smoking was higher in women than in men, sug-
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Power estimates for the Colaus study. Power for 
various sample sizes in unmatched case-control stud-
ies. Arbitrary allelic frequency of 0.3, a disease prevalence of 
50% and a type 1 error rate of 10-7taking into account 
500'000 genetics markers. Curves are for estimated genetic 
effects (odds ratios) of 1.2 to 1.8. The numbers of cases for 
main CVRFs in the Colaus study are: Hypertension: 2268. 
Dyslipidemia: 2021. Obesity: 963. Smoking (> 25 cigarettes/ 
day): 746. Type 2 diabetes: 398. Coronary heart disease: 262. 
Law HDL: 170. 
gesting that the "gender gap" regarding smoking no longer 
exists for middle-aged subjects. 
The high prevalence of CVRFs in this study population 
underscores the necessity to increase disease awareness, to 
improve screening in high risk subjects and to promote 
prevention bath at the public health and individual level. 
Recently, an increasing number of reports have demon-
strated the power of whole genome association studies 
approach in complex diseases such as diabetes [29], obes-
ity [ 3 0 J and cardiovascular disease [ 31]. The size of the 
CoLaus study, the population-based design and the in-
depth phenotypisation were chosen in order to harness 
the power of this technology using dichotomous and con-
tinuous trait analyses. In particular, this ensures an identi-
cal phenotypisation in cases and controls, which has been 
a limitation in some of the recentlypublished reports [32] 
and allows to study complex traits such as the metabolic 
syndrome. Combined analysis of our results with other 
datasets has already allowed to identify new genetic deter-
minants associated with circulating LDL-plasma levels 
[ 17] ( similar results were published concomitantly by 
other groups [33,34]) and determinants associated with 
height [35]. Additional analysis are currently ongoing. 
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Power estimates for the Colaus study. Power for the 
analysis of systolic blood pressure as a continuous 
variable. Power calculations using a continuous outcome for 
independent subjects, with an additive mode of action for the 
allele and a type 1 error rate of 10-7. Calculations were done 
for various minor allele frequencies (0.1 to 0.5). 
Perspectives 
A more comprehensive characterization of the Colaus par-
ticipants is currently ongoing. First ail participants aged 35 
ta 65 were solicited to undergo a psychiatrie investigation 
based on a semi-structured diagnostic interview. In addi-
tion, 500 subjects were assessed for CV functional measure-
ments. Indeed several previous studies have revealed 
associations between mood disorders and, in particular 
depression, and CVRFs and CV diseases (reviewed in [36]). 
The availability of a simultaneous CV and psychiatrie phe-
notype will allow us to further explore the epidemiologic 
and potentially a genetic basis for this association. Finally, 
500 randomly selected non-diabetic individuals underwent 
a 2 hour glucose tolerance test. The results from these inves-
tigations will be reported separately. 
A longitudinal follow-up of all participants in the CoLaus 
study is planned and shall provide essential data for 
trends over time of major CVRFs and on incident cases of 
CV diseases. In the current cross-sectional study, partici-
pants were asked whether they consented to be contacted 
for foliow-up, with > 90% favorable responses. 
Conclusion 
In summary, these initial results from the CoLaus study 
show that the prevalence of main CVRFs is high in the 
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caucasian population of Lausanne, and in particular in 
men. This emphasizes the need for continued epidemio-
logical monitoring and for strengthening interventions to 
reduce the prevalence and severity of CVRFs in this popu-
lation. This population-based studywith over 6000 exten-
sively characterized and genotyped participants 
constitutes a unique resource to identify new or replicate 
suspected or known molecular determinants of CVRFs 
and associated diseases. 
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